Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Erlotinib for Duodenal Polyps in FAP
NCT02961374Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of erlotinib in familial adenomatous polyposis (FAP), sponsored by National Cancer Institute. Started Oct 2017; status: completed.
02
Drugs
erlotinib
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT02961374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961374.